Contingency Fee Representation
Our legal team represents clients on a contingency fee basis. This means there are no out of pocket costs to you and the law firm advances all costs to prosecute the asbestos exposure lawsuit. There will only be a fee when we are victorious and achieve justice for your asbestos exposure related to lung cancer or mesothelioma.
What is Contingency Fee Representation?
Contingency fee representation is employed to level the playing field against a multitude of deep pocket defendants who employ legions of defense attorneys to defend the mesothelioma or asbestos exposure case. This serves to promote justice for the client by ensuring that the legal team’s interests in obtaining substantial compensation are the same as the client’s interest in obtaining maximum compensation.
Strong Representation with Adequate Resources
Attorneys for plaintiffs in asbestos exposure lawsuits only source of income is from being victorious with your case. The attorney fee split in an asbestos exposure lawsuit is generally 40% to the law firm and 60% to the client of the total proceeds. This is what we work for to achieve justice and ensure strong representation for individuals against large multi-billion dollar international defendants.
Recieve answers to any questions you have about the asbestos exposure litigation process.
Are Mesothelioma Settlements Taxable?
The proceeds you receive via settlement or verdict for your asbestos exposure case are in general not subject to income taxes. Compensation for asbestos exposure including reimbursement of medical costs and pain and suffering damages make you whole after suffering losses and are thus not considered income for tax purposes. However, it is important to obtain professional accountant services to determine if damages for lost wages recovered are subject to taxation and what tax liability you may have which depends on individual circumstances.
On Thursday, 14th March 2019, A California jury held two construction companies and oil refineries accountable for the employee's testicular mesothelioma....read more
Researchers are devising a technique, called CAR T-cell (chimeric antigen receptors) therapy in which patient's T cells are reprogrammed to specifically...read more
In the year 2014, Pemetrexed injection Alimta received approval from the FDA along with cisplatin for the initial treatment of patients with malignant...read more